Chicago, IL – Today, Lyft and Continuum Clinical announced a partnership that will help to provide transportation solutions for patients who are enrolled in pharmaceutical clinical trials.
This partnership represents the first of its kind among pharmaceutical vendors who work on behalf of pharmaceutical companies to recruit patients for clinical trials.
“We’re thrilled to partner with Lyft to offer patients enrolled in clinical trials a new level of convenience,” said Nariman Nasser, vice president of site optimization at Continuum Clinical. “We believe that this service will make enrolling and staying in a study easier, especially for those patients with limited resources and access to transportation.”
Lack of transportation is frequently cited as a barrier to retaining patients in clinical trials. Through Continuum’s partnership with Lyft, patients enrolled in clinical trials will be able to use the Lyft app to secure transportation to and from the trial site, free of charge.
The program will help to ensure that patients enrolled in the trials won’t miss appointments, which may potentially disqualify them from the trial. Continuum plans on trialing the Lyft program this quarter for a national study on lupus.
“Through our partnership with Continuum Clinical, we’re able to provide patients with safe, affordable and reliable rides,” said Gyre Renwick, head of enterprise healthcare partnerships at Lyft. “We look forward to working with Continuum to help the community get around more efficiently.”
In 2016, Lyft partnered with a number of senior care providers and healthcare systems for non-emergency transportation services. Continuum Clinical will be a preferred provider for clinical trial transportation solutions.
For over 20 years, Continuum Clinical has worked with eight of the top ten pharmaceutical companies around the world to recruit patients for clinical trials through integrated marketing efforts. They have recruited patients for more than 600 studies in over 75 disease states. Currently, Continuum is working with over 1,900 active study sites throughout the U.S.
About Continuum Clinical
Continuum Clinical is a global healthcare research and communications company. With over thirty years of experience, Continuum Clinical brings together a unique blend of world-class experience in key disciplines, including observational research, marketing, communications, site optimization health economics, and outcomes research. We excel in providing seamless resources for pharmaceutical and biotech products - from patient recruitment and retention for clinical trials to late stage studies and health economics and outcomes research. Continuum Clinical provides a unique blend of resources and perspectives, proven expertise, and innovative solutions throughout the entire continuum of a product’s lifecycle - from pre-launch into the real world. Headquartered in the US, Continuum Clinical has employees in Europe and expanded worldwide network of resources. www.continuumclinical.com.
About Lyft
Lyft was founded in June 2012 by Logan Green and John Zimmer to improve people's lives with the world's best transportation. Lyft is the fastest growing rideshare company in the U.S and is available in more than 200 cities. Lyft is preferred by drivers and passengers for its safe and friendly experience, and its commitment to effecting positive change for the future of our cities. For more information on Lyft for Healthcare, visit http://get.lyft.com/healthcare/
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.